Aikawa Yoshiyuki, Chairman and Chief Executive Officer of SBC Medical Group Holdings Inc (NASDAQ:SBC), reported the sale of 4,422,900 shares of common stock on March 6, 2026, at $2.12 per share, resulting in gross proceeds of $9,376,548.
The transaction was executed indirectly through Aikawa Equity Management Co., Ltd., and is disclosed in a Form 4 filing with the Securities and Exchange Commission. After the sale, Aikawa directly holds 82,404,460 shares of SBC Medical Group Holdings Inc. In addition to his direct holdings, Aikawa indirectly holds 5,000,000 shares through GODO Kaisha Aikawa Investment.
Market prices have moved since the trade. SBC shares currently trade at $3.75, a 77% increase from the $2.12 per-share sale price reported in the filing, though the stock is down 13% year-to-date.
The Form 4 filing also references derivative activity tied to the company’s share purchase agreements, noting transactions involving both Put and Call Options.
Beyond the insider sale, SBC Medical has advanced a package of strategic and capital initiatives. The company announced a Form S-3 Registration Statement that has received SEC clearance, creating a shelf registration that permits future offerings of up to $50 million in equity. Concurrently, SBC established a $20 million share repurchase program.
In a move to expand its addressable market, SBC Medical made a minority equity investment in OrangeTwist, marking its entry into the U.S. aesthetics sector. The company described the investment as part of a broader global expansion strategy and said it establishes a framework for collaboration with OrangeTwist and the latter’s institutional shareholders. OrangeTwist has grown to 24 locations, with SBC’s support enabling the acquisition of six new med spa locations in Colorado and Nevada.
On the leadership and technology front, SBC named Sheng-FU Hsiao as Chief Technology Officer with responsibility for guiding the company’s transition to an AI-driven infrastructure.
Separately, third-party analysis cited in filings indicates that, at current market levels, SBC appears undervalued according to InvestingPro, with more detailed findings available in that platform’s Pro Research Report.
The filings and company actions together present a mix of insider liquidity, capital-marketing flexibility, targeted investment in U.S. aesthetics, and focused technology leadership changes. Observers will be able to track the combined effect of these moves on SBC’s operational footprint and capital structure as the company executes its stated initiatives.